We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
TEVIMBRA Beigene Aus Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Apr-2024
Active ingredients
tislelizumab
Proposed indication
Indicated for the first-line treatment of locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Application type
A (new medicine)
Publication date
Apr-2024